We assessed the association of TAP1 and TAP2 levels with tumor grade and other clinicopathologic features such as stage, HER2/neu status, and estrogen receptor (ER) and progesterone receptor (PR) expression levels in an attempt to identify the relationship between loss of expression and aggressive tumor behavior. This evidence concerns the gene ESR1 and neoplasm.